他们利用 CRISPR/Cas 介导的一体化方法，在符合药品生产质量管理规范（Good Manufacturing Practice，GMP）的平台上，将抗 EBV（gp350）的嵌合抗原受体（Chimeric Antigen Receptor，CAR）插入 T 细胞受体（T-cell receptor，TRAC）位点，同时敲除糖皮质激素受体（Glucocorticoid Receptor ...

为攻克 EBV 阳性伯基特淋巴瘤（BL）治疗难题，研究人员开展 gp350-CAR-T 疗法研究，证实其抑瘤效果，为临床治疗带来新策略。 # 靶向 gp350 的 CAR-T 疗法：EBV 阳性伯基特淋巴瘤治疗的新曙光 在医学的微观世界里，病毒与肿瘤的 “暗战” 一直是科研人员关注的焦点。

Epstein-Barr virus (EBV), a member of the herpesvirus family, is a highly common human pathogen that can remain latent in B lymphocytes after the primary infection. Although this latent state is ...

EBV infects 95% of people and doesn’t usually ... as well as an antigen derived from gp350. Most earlier vaccine attempts have targeted gp350 alone. In animal studies, a similar vaccine ...